Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
The BioCentury Show
BioCentury
Audio-CD.at Indie Podcasts: Wiener Börse, Sport, Musik (und mehr)
Christian Drastil Comm. (Agentur für Investor Relations und Podcasts)
Uranium Market Minute Podcast
Justin Huhn
Green Ticker Tales
Greentickertales
The Diggintravel Podcast
Iztok Franko
小資變有錢｜Dr.Selena生活理財王
Dr.Selena 楊倩琳博士
Curiosity Chronicle
Sahil Bloom
今日股市 | 薪伊谈股票投资
薪伊Elaine
Handelsblatt Morning Briefing - News aus Wirtschaft, Politik und Finanzen
Friederike Hofmann, Sven Prange und die Handelsblatt Redaktion, Handelsblatt
Speak Up: Develop Your Executive Presence & Leadership Communication Style
Laura Camacho
" The Power of Vocal Dynamics "
Sheena Walker "The Celebrity Class Speaker "
Business of Machining
John Grimsmo & John Saunders
Tax Notes Talk
Tax Notes
ICH WIR ALLE. Selbst + Team + Werte-Entwicklung
SHORT CUTS GmbH design + kommunikation
Trends Beleggen
Roularta Media Group, Trends
Auslegungssache – der c't-Datenschutz-Podcast
c't Magazin
AICPA Personal Financial Planning (PFP)
AICPA & CIMA
The Pool Guy Podcast Show
David Van Brunt
The Agile Brand with Greg Kihlström®: Expert Mode Marketing Technology, AI, & CX
The Agile Brand
Freight 360
Freight 360
t3n Arbeit in Progress
t3n Digital Pioneers
Kurzerklärt - Der Jurapodcast
Nomos Verlag & Sebastian Baur
The SupplyChainBrain Podcast
Bob Bowman
Økonomiamatørene
Horde
Dodge Woodall Network
Dodge Woodall
The Dirt on Flowers
Shannon Allen and Lyndsay Biehl
THE DR. BETH'S podcast
Dr. Beth
Leverage Addicts
MHQ
iGaming Daily
SBC Media
The James Brown Commentary
James A. Brown
Retire at New Heights with Johnnie Roberts
Johnnie Roberts
Trinity Sparke Sounds; An educational leadership podcast
Trinity MAT
Velvet Rope Playbook
Mark Satterfield
The Mishal Husain Show
Bloomberg
Wade Keller Pro Wrestling Post-shows
Pro Wrestling Torch
Nacktes Geld
Paul Brandenburg
EntreArchitect Podcast with Mark R. LePage
EntreArchitect // Gābl Media
Business
BioCentury
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank...
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in S...
ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The...
Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing th...
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCen...
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, accordi...
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-fou...
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting s...
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI...
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower re...
Caution: This episode of The BioCentury Show contains strong language.In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slo...
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypoth...
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move id...
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need for large-scale capital, alongside PE firms’ increasing ability to con...
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, but the level of anxiety in biotech doesn’t reflect the “extraordinary s...
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by techno...
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.If you c...
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic ca...
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though...
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of bio...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.